Mysterious BioNTech strikes $60m-plus cancer T cell deal with Lilly
This article was originally published in Scrip
Mainz-based BioNTech, which once called itself "the biggest European biotech that you have never heard of", has announced a research collaboration in cancer immunotherapies with Eli Lilly centered around the German company's assets and platform in T cell receptors (TCR) and chimeric antigen receptor T cells (CAR T cells). BioNTech will receive a $30m signing on fee and Lilly will make a $30m equity investment in BioNTech's subsidiary, Cell & Gene Therapies.
You may also be interested in...
BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.